© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
January 11, 2022
AGTC-501 is a recombinant AAV vector-based gene therapy developed for the treatment of X-linked retinitis pigmentosa.
January 07, 2022
According to the company, 4D-150 is a dual-transgene, intravitreal gene therapy designed to inhibit four distinct angiogenic factors to prevent angiogenesis and reduce vascular permeability for the treatment of wet AMD.
January 07, 2022
Team at University of California, Irvine provides an understanding of the mechanisms underlying the pathologies of certain gene mutations.
January 06, 2022
The novel gene therapy product candidate is being developed as a potential single intravitreal administration for blue cone monochromacy by delivering a functional copy of the OPN1LW gene.
January 03, 2022
The grant will provide Steven DeVries, MD, PhD, the opportunity to travel to Kyoto, Japan and learn from scientists at Ritsumeikan University about the process of growing 3D retinal organoids from stem cells, a technique first developed in Japan.
December 29, 2021
Researchers have found that study participants with healthy eyes and no history of AMD had thinner retinas if they carried the genes that put them at risk.
December 27, 2021
In light of another unprecedented year filled with technological advancements and pivots as a result of the pandemic, Joshua Mali, MD, offers his top 5 predictions in ophthalmology for 2022.
December 23, 2021
A team of researchers with the West Virginia School of Medicine are studying how a benign virus can make new treatments for eye diseases possible.
December 23, 2021
A team of researchers from Thomas Jefferson University have found that immune cells could be doing much more than first thought in protecting our eyes.
December 22, 2021
The cell-by-cell atlas will help in the study of eye disorders and development of cell therapy to replace damaged eye tissue.